evidence table

Alpha Lipoic Acid Cognitive Performance Randomized Trial Evidence Table

Name: Alpha Lipoic Acid Cognitive Performance Randomized Trial Evidence Table
Creator: Migaku
License: https://creativecommons.org/licenses/by/4.0/

Structured evidence table for Alpha Lipoic Acid Cognitive Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topic	claim	evidence level	citation	source
Alpha Lipoic Acid Cognitive Performance Randomized Trial	This review summarizes current evidence on nutritional compounds that target aging-related pathways, focusing on interventions that influence mitochondrial health, cognitive performance, immune function, metabolic regulation, and maintenance of muscle mass in older adults.	4	Kurtz JA (2026)	Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits.
Alpha Lipoic Acid Cognitive Performance Randomized Trial	Recent findings Evidence indicates that several targeted nutrients, including protein, probiotics, antioxidants, and emerging mitochondrial-support compounds, may contribute to healthy aging.	4	Kurtz JA (2026)	Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits.
Alpha Lipoic Acid Cognitive Performance Randomized Trial	A personalized, evidence-informed supplementation strategy integrated with exercise and balanced nutrition may help optimize physiological function in aging adults.	4	Kurtz JA (2026)	Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits.
Alpha Lipoic Acid Cognitive Performance Randomized Trial	Purpose of review Aging is marked by progressive physiological decline driven by chronic inflammation, mitochondrial dysfunction, and impaired metabolic and musculoskeletal resilience.	4	Kurtz JA (2026)	Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits.
Alpha Lipoic Acid Cognitive Performance Randomized Trial	Objectives This review aims to critically synthesize mechanistic, preclinical, and clinical evidence on α-lipoic acid and biotin as candidate neuroprotective agents in neurodegenerative diseases, with emphasis on shared signaling pathways, therapeutic potential, generally favorable safety profiles, and translational limitations.	4	Aguilera-Méndez A (2026)	Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.
Alpha Lipoic Acid Cognitive Performance Randomized Trial	The evidence was qualitatively analyzed with attention to biological plausibility, consistency across models, and clinical relevance.	4	Aguilera-Méndez A (2026)	Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.
Alpha Lipoic Acid Cognitive Performance Randomized Trial	In contrast, clinical evidence remains heterogeneous, with more extensive evaluation of biotin in progressive multiple sclerosis and more limited or exploratory findings for ALA across neurodegenerative disorders.	4	Aguilera-Méndez A (2026)	Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.
Alpha Lipoic Acid Cognitive Performance Randomized Trial	Background Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis, represent a major global health burden and share convergent pathogenic mechanisms, such as mitochondrial dysfunction, oxidative stress, neuroinflammation, calcium imbalance, and neuronal loss.	4	Aguilera-Méndez A (2026)	Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.